Results 71 to 80 of about 4,022 (166)

Emergence of cefiderocol resistance during therapy in NDM-5–producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations

International Journal of Infectious Diseases
Cefiderocol, a siderophore-conjugated cephalosporine, is a promising drug used to treat infection with carbapenem-resistant gram-negative bacteria. Here, we report a case of pneumonia induced by multiple gram-negative pathogens, including a carbapenem ...
Luc Deroche, Albane Rozenholc, François Arrivé, Jean-Philippe Martellosio, Gwenaël Le Moal, Arnaud W. Thille, Olivier Barraud, Sandrine Marchand, Julien M. Buyck   +8 more
doaj   +1 more source

Addressing antimicrobial resistance: Structural insights into cefiderocol’s mode of action and emerging resistance mechanisms

Journal of Infection and Public Health
Cefiderocol represents a significant advancement in the treatment of multidrug-resistant Gram-negative bacterial infections. Its unique uptake mechanism, leveraging bacterial iron transport pathways for membrane permeation, sets it apart from ...
Mohd Zulkifli Salleh
doaj   +1 more source

In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis

Journal of Global Antimicrobial Resistance
: Objectives: Gram-negative pathogens causing respiratory infection in people with cystic fibrosis and bronchiectasis are becoming progressively more resistant to conventional antibiotics. Although cefiderocol is licenced for the treatment of infections
Michael M Tunney, J Stuart Elborn, Chloe S McLaughlin, Christopher M Longshaw   +3 more
doaj   +1 more source

Cefiderocol. Summary and conclusions

Revista Española de Quimioterapia, 2022
Mensa, José, Barberán, José
openaire   +2 more sources

Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol

Scientific Reports
Klebsiella pneumoniae carbapenemase (KPC) is a frequent and widespread carbapenemase, with over 260 variants identified. While KPC often evolves resistance to ceftazidime-avibactam, cefiderocol remains a key treatment option.
Sidonie Hanna, Kevin La, Yutaka Yoshii, Maud Gits-Muselli, Imane El Meouche, Yasmine Benhadid-brahmi, Stéphane Bonacorsi, André Birgy   +7 more
doaj   +1 more source

In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form–alone and in combination with bacteriophages

Scientific Reports
Multi-drug resistant Gram-negative pathogens are increasingly difficult-to-treat perpetrators of infections. New, innovative, and more multifaceted therapies for the treatment of multi-drug resistant strains are thus urgent to hinder further drug ...
Rima Fanaei Pirlar, Nexhmije Halili, Tina Travnik, Andrej Trampuz, Svetlana Karbysheva   +4 more
doaj   +1 more source

Small colony variants and cefiderocol resistance in clinical <i>Escherichia coli</i>: an <i>in vitro</i> mechanistic study. [PDF]

Front Microbiol
Syed MA, Pu D, Song R, Zhao J, Cao B.
europepmc   +1 more source

Nutrient-driven small-colony variants as an adaptive outcome in Carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]

Curr Res Microb Sci
Moheb S, Sanchez SD, Luu I, Varnado A, Traglia GM, Lopez K, Escalante J, Rodriguez C, Tuttobene MR, Tolmasky ME, Bonomo RA, Actis LA, Rao GG, Pasteran F, Ramirez MS.   +14 more
europepmc   +1 more source

Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative Infections. [PDF]

Infect Drug Resist
Melchio M, Briano F, Sepulcri C, Vena A, Bassetti M.   +4 more
europepmc   +1 more source

Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes. [PDF]

J Antimicrob Chemother
Cantón R, García-Castillo M, Hernández-García M, Sastre-Femenía MÀ, López-Causapé C, Ruiz-Garbajosa P, García Labrador L, Longshaw C, Oliver A.   +8 more
europepmc   +1 more source